Journal of Pain & Relief
Open Access

Research Article

An Observational Study on Lignocaine Infusion for Intractable Chronic Pain

Amir Aslam^1*, Jaipaul Singh² and Satyan Rajbhandari^2,3

¹University of Calgary, Alberta, Canada

²School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK

³Department of Diabetology and Endocrinology, Lancashire Teaching Hospital NHS Trust, Chorley and South Ribble District General Hospital, Preston Road, Chorley, UK

*Corresponding Author:

Amir Aslam
Assistant Clinical Professor University of Calgary
Family Physician at Eaton Centre Medical Clinic, 751 3rd Street
Suite 417, Calgary, Alberta, Canada
Email: AmirAslam@hotmail.com

Received date: April 19, 2016; Accepted date: July 05, 2016; Published date: July 08, 2016

Citation: Aslam A, Singh J, Rajbhandari S (2016) An Observational Study on Lignocaine Infusion for Intractable Chronic Pain. J Pain Relief 5:255. doi:10.4172/2167-0846.1000255

Copyright: © 2016 Aslam A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Objective: This study assessed the efficacy of lignocaine infusion as a treatment for painful diabetic neuropathy (PDN) groups compared to chronic pain (non-PDN group) in challenging cases where conventional treatment is not helpful.

Methods: A total 11 patients participated in the study with 7 patients referred from pain clinic (non-PDN group) and 4 for patients referred from diabetic foot clinic (PDN group) for lignocaine infusion as a treatment for chronic pain. Both groups of participants were on multiple combination of pain medication with minimal help. All the subjects gave consent for participation and filled out McGill short form (SF) questionnaire before and after the lignocaine infusion.

Results: The results show 33% reduction of visual analogue pain score after lignocaine infusion in PDN group compared to 11% reduction of visual analogue pain score in non-PDN group. These data were statistically significant (p<0.05). Similarly, there was a significant (p<0.05) reduction of affective pain score with 41% after lignocaine infusion in PDN group compared to 21% in non-PDN group. In contrast, the sensory pain score reduction after lignocaine infusion was 23% in PDN group compared to 17% in non-PDN group. These data were statistically not significant (p>0.05). All 11 patients had no reported adverse effects and their observations were in normal limits throughout the lignocaine infusion.

Conclusion: Overall, the study showed that lignocaine infusion is both effective and safe in reducing chronic intractable pain when conventional treatments are intolerable or not helpful. It is more effective in painful diabetic neuropathy patients compared to other causes of chronic pain.

Keywords